利润表（新华制药）
| 上市前/上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 |
| 报表类型 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 |
| 一、营业总收入(元) | 6,734,166,240.75 | 4,732,481,467.24 | 2,474,697,457.66 | 8,100,844,707.33 | 6,497,534,830.57 | 4,672,269,049.13 | 2,639,665,769.78 |
| 营业收入(元) | 6,734,166,240.75 | 4,732,481,467.24 | 2,474,697,457.66 | 8,100,844,707.33 | 6,497,534,830.57 | 4,672,269,049.13 | 2,639,665,769.78 |
| 二、营业总成本(元) | 6,337,089,365.67 | 4,414,193,942.13 | 2,328,929,009.30 | 7,530,904,783.94 | 6,039,257,829.40 | 4,311,750,429.21 | 2,460,141,970.67 |
| 营业成本(元) | 5,151,913,375.72 | 3,547,931,805.24 | 1,795,729,697.76 | 5,709,142,351.00 | 4,607,407,658.38 | 3,281,046,254.21 | 1,811,323,065.52 |
| 研发费用(元) | 326,669,940.69 | 243,105,634.20 | 141,905,763.44 | 419,239,700.90 | 341,281,879.49 | 235,529,909.24 | 112,119,587.26 |
| 营业税金及附加(元) | 51,662,674.60 | 36,899,978.55 | 18,434,857.09 | 92,175,276.66 | 78,604,110.04 | 60,476,643.03 | 42,055,615.47 |
| 销售费用(元) | 504,223,794.96 | 403,565,129.41 | 291,064,033.27 | 780,171,394.31 | 643,446,889.77 | 487,038,936.17 | 352,901,998.18 |
| 管理费用(元) | 292,405,195.99 | 181,073,486.83 | 78,840,015.11 | 513,824,781.93 | 359,156,212.14 | 246,316,699.21 | 126,174,409.90 |
| 财务费用(元) | 10,214,383.71 | 1,617,907.90 | 2,954,642.63 | 16,351,279.14 | 9,361,079.58 | 1,341,987.35 | 15,567,294.34 |
| 其中：利息费用(元) | 28,115,663.07 | 17,868,283.95 | 9,217,078.08 | 41,148,585.76 | 31,708,976.46 | 21,488,813.56 | 11,804,437.54 |
| 其中：利息收入(元) | 8,324,746.77 | 4,581,339.55 | 2,881,003.92 | 12,300,491.07 | 9,710,348.87 | 6,731,842.63 | 3,701,993.16 |
| 三、其他经营收益 | |||||||
| 加：投资收益(元) | 8,399,571.55 | 9,516,606.83 | 1,188,728.16 | 9,583,372.02 | 9,689,034.62 | 8,286,352.28 | 78,030.02 |
| 其中：对联营企业和合营企业的投资收益(元) | 217,371.55 | 1,334,406.83 | 1,188,728.16 | 1,417,610.42 | 1,523,273.02 | 120,590.68 | 78,030.02 |
| 资产处置收益(元) | 1,201,542.62 | 1,240,258.42 | 845,111.01 | 8,733,639.41 | 8,280,514.96 | 1,274,182.44 | 525,019.96 |
| 资产减值损失(元) | -48,313,538.64 | -48,313,538.64 | - | -69,282,694.12 | -44,340,776.07 | -44,340,776.07 | - |
| 信用减值损失(元) | -8,073,501.52 | -8,193,415.41 | 70,000.00 | -10,294,468.42 | -3,088,314.61 | -3,477,647.35 | 500.00 |
| 其他收益(元) | 47,979,403.05 | 35,032,548.75 | 22,684,697.21 | 25,902,239.33 | 18,052,760.69 | 11,695,552.06 | 5,670,706.38 |
| 四、营业利润(元) | 398,270,352.14 | 307,569,985.06 | 170,556,984.74 | 534,582,011.61 | 446,870,220.76 | 333,956,283.28 | 185,798,055.47 |
| 加：营业外收入(元) | 659,426.07 | 326,560.85 | 193,820.84 | 5,537,126.16 | 4,193,692.89 | 632,015.65 | 359,782.90 |
| 减：营业外支出(元) | 6,012,150.78 | 4,532,708.22 | 1,979,283.56 | 7,433,412.75 | 4,587,146.80 | 2,642,486.67 | 1,238,527.22 |
| 五、利润总额(元) | 392,917,627.43 | 303,363,837.69 | 168,771,522.02 | 532,685,725.02 | 446,476,766.85 | 331,945,812.26 | 184,919,311.15 |
| 减：所得税费用(元) | 37,468,356.21 | 30,597,489.83 | 23,507,423.62 | 26,578,700.01 | 46,187,008.38 | 56,265,379.99 | 30,908,896.72 |
| 六、净利润(元) | 355,449,271.22 | 272,766,347.86 | 145,264,098.40 | 506,107,025.01 | 400,289,758.47 | 275,680,432.27 | 154,010,414.43 |
| (一)按经营持续性分类 | |||||||
| 持续经营净利润(元) | 355,449,271.22 | 272,766,347.86 | 145,264,098.40 | 506,107,025.01 | 400,289,758.47 | 275,680,432.27 | 154,010,414.43 |
| (二)按所有权归属分类 | |||||||
| 归属于母公司股东的净利润(元) | 344,079,950.67 | 265,404,417.68 | 141,879,437.62 | 496,512,201.25 | 391,968,372.92 | 269,807,157.85 | 151,603,818.36 |
| 少数股东损益(元) | 11,369,320.55 | 7,361,930.18 | 3,384,660.78 | 9,594,823.76 | 8,321,385.55 | 5,873,274.42 | 2,406,596.07 |
| 扣除非经常性损益后的净利润(元) | 321,411,536.21 | 249,366,401.77 | 137,727,454.74 | 461,535,415.37 | 362,721,894.04 | 252,506,003.03 | 147,158,093.14 |
| 七、每股收益 | |||||||
| 一、基本每股收益(元) | 0.50 | 0.39 | 0.21 | 0.74 | 0.58 | 0.40 | 0.23 |
| 二、稀释每股收益(元) | 0.50 | 0.38 | 0.21 | 0.72 | 0.57 | 0.39 | 0.22 |
| 八、其他综合收益(元) | 74,961,072.66 | 27,326,906.39 | 815,327.77 | 1,736,014.71 | 24,317,701.91 | 13,873,006.87 | 7,709,824.55 |
| 归属于母公司股东的其他综合收益(元) | 75,223,458.18 | 27,600,823.60 | 807,373.60 | 1,491,268.41 | 23,870,787.70 | 13,346,960.91 | 7,890,797.98 |
| 归属于少数股东的其他综合收益(元) | -262,385.52 | -273,917.21 | 7,954.17 | 244,746.30 | 446,914.21 | 526,045.96 | -180,973.43 |
| 九、综合收益总额(元) | 430,410,343.88 | 300,093,254.25 | 146,079,426.17 | 507,843,039.72 | 424,607,460.38 | 289,553,439.14 | 161,720,238.98 |
| 归属于母公司所有者的综合收益总额(元) | 419,303,408.85 | 293,005,241.28 | 142,686,811.22 | 498,003,469.66 | 415,839,160.62 | 283,154,118.76 | 159,494,616.34 |
| 归属于少数股东的综合收益总额(元) | 11,106,935.03 | 7,088,012.97 | 3,392,614.95 | 9,839,570.06 | 8,768,299.76 | 6,399,320.38 | 2,225,622.64 |
| 公告日期 | 2024-10-30 | 2024-08-23 | 2024-04-26 | 2024-03-29 | 2023-10-28 | 2023-08-25 | 2023-04-21 |
| 审计意见(境内) | 标准无保留意见 | ||||||
| 原始财报文件下载 | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) |
| 上市前/上市后 |
| 报表类型 |
| 一、营业总收入(元) |
| 营业收入(元) |
| 二、营业总成本(元) |
| 营业成本(元) |
| 研发费用(元) |
| 营业税金及附加(元) |
| 销售费用(元) |
| 管理费用(元) |
| 财务费用(元) |
| 其中：利息费用(元) |
| 其中：利息收入(元) |
| 三、其他经营收益 |
| 加：投资收益(元) |
| 其中：对联营企业和合营企业的投资收益(元) |
| 资产处置收益(元) |
| 资产减值损失(元) |
| 信用减值损失(元) |
| 其他收益(元) |
| 四、营业利润(元) |
| 加：营业外收入(元) |
| 减：营业外支出(元) |
| 五、利润总额(元) |
| 减：所得税费用(元) |
| 六、净利润(元) |
| (一)按经营持续性分类 |
| 持续经营净利润(元) |
| (二)按所有权归属分类 |
| 归属于母公司股东的净利润(元) |
| 少数股东损益(元) |
| 扣除非经常性损益后的净利润(元) |
| 七、每股收益 |
| 一、基本每股收益(元) |
| 二、稀释每股收益(元) |
| 八、其他综合收益(元) |
| 归属于母公司股东的其他综合收益(元) |
| 归属于少数股东的其他综合收益(元) |
| 九、综合收益总额(元) |
| 归属于母公司所有者的综合收益总额(元) |
| 归属于少数股东的综合收益总额(元) |
| 公告日期 |
| 审计意见(境内) |
| 原始财报文件下载 |
Showing 1 to 44 of 44 entries